---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-038736"
form_type: "8-K"
ticker: "SHPH"
cik: "0001757499"
company_name: "Shuttle Pharmaceuticals Holdings, Inc."
filed_at: "2023-10-30T23:59:59+00:00"
generated_at: "2026-06-09T06:07:53.413904+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Shuttle Pharma licenses predictive biomarker IP from Georgetown for prostate cancer RT

## Summary
- Exclusive license for patent application 17/476,184 ("Predictive Biomarkers for Adverse Effects of Radiation Therapy") from Georgetown University.
- Upfront payment, maintenance fees, and milestone payments tied to validation trial, FDA approval, and commercial sales; 5% earned royalty on net sales.
- IP developed by CEO Dr. Anatoly Dritschilo, Principal Scientist Dr. Scott Grindrod, and Georgetown researchers.
- Company completed Phase I/II NIH SBIR contracts for the biomarker program; plans to seek Phase IIb SBIR bridge funding.
- Program targets a blood test to predict radiation therapy outcomes for ~66,000 prostate cancer patients annually in the US.

## SEC filing metadata
- accession: 0001493152-23-038736
- form_type: 8-K
- ticker: SHPH
- cik: 0001757499
- company_name: Shuttle Pharmaceuticals Holdings, Inc.
- filed_at: 2023-10-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1757499/000149315223038736/0001493152-23-038736-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1757499/000149315223038736/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-038736
- JSON: https://secwatch.observer/filing/0001493152-23-038736.json
- Plain text: https://secwatch.observer/filing/0001493152-23-038736.txt

## Key facts
- Material Agreements
  Shuttle Pharmaceuticals Holdings, Inc. entered into License Agreement with Georgetown University (effective 2023-10-24).
  - Action: entry
  - Agreement: license
  - Counterparty: Georgetown University
  - Effective: 2023-10-24
  source text: On October 24, 2023, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), entered into an exclusive licensing agreement (the “License Agreement”) with Georgetown University (“Georgetown”) pursuant to which Georgetown agreed to license the intellectual property known as “Predictive Biomarkers for Adverse Effects of Radiation Therapy” (U.S. Patent Application No. 17/476,184, filed on September 15, 2021) (the “Patent Rights”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1757499/000149315223038736/0001493152-23-038736-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.